Oragenics
OGEN
11 hedge funds and large institutions have $2.48M invested in Oragenics in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
8% more capital invested
Capital invested by funds: $2.29M → $2.48M (+$186K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.01% less ownership
Funds ownership: 0.01% → 0.01% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$768K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133K |
| 3 |
VF
Virtu Financial
New York
|
+$114K |
| 4 |
Barclays
London,
United Kingdom
|
+$72.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$49K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$41.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$35K |
OGEN Hedge Fund Activity: Q4 2018 in Review
11 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q4 2018, worth a combined $2.48M — up 8.1% from $2.29M a quarter earlier.
Fund positioning in OGEN was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $768K. The largest seller was MSD Partners, exiting entirely with an estimated $49K sold.
- 11 institutional investors held Oragenics (OGEN) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $2.48M of Oragenics stock for Q4 2018, up 8.1% quarter-over-quarter.
- 3 funds opened new Oragenics positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest Oragenics buyer in Q4 2018 was BlackRock, an estimated $768K added.
- The largest Oragenics seller in Q4 2018 was MSD Partners, an estimated $49K sold.
Based on aggregated 13F filings for Q4 2018.